000			01912 a2200589 4500
005			20250515205748.0
264		0	_c20101104
008			201011s 0 0 eng d
022			_a1476-5497
024	7		_a10.1038/ijo.2010.21 _2doi
040			_aNLM _beng _cNLM
100	1		_aAronne, L J
245	0	0	_aA clinical trial assessing the safety and efficacy of taranabant, a CB1R inverse agonist, in obese and overweight patients: a high-dose study. _h[electronic resource]
260			_bInternational journal of obesity (2005) _cMay 2010
300			_a919-35 p. _bdigital
500			_aPublication Type: Journal Article; Multicenter Study; Randomized Controlled Trial
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAmides _xadministration & dosage
650	0	4	_aAnti-Obesity Agents _xadministration & dosage
650	0	4	_aBody Mass Index
650	0	4	_aBody Weight _xdrug effects
650	0	4	_aDiet, Reducing
650	0	4	_aDouble-Blind Method
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aMale
650	0	4	_aMetabolic Syndrome _xdrug therapy
650	0	4	_aMiddle Aged
650	0	4	_aObesity _xdrug therapy
650	0	4	_aPyridines _xadministration & dosage
650	0	4	_aReceptor, Cannabinoid, CB1 _xagonists
650	0	4	_aRisk Assessment
650	0	4	_aTreatment Outcome
650	0	4	_aYoung Adult
700	1		_aTonstad, S
700	1		_aMoreno, M
700	1		_aGantz, I
700	1		_aErondu, N
700	1		_aSuryawanshi, S
700	1		_aMolony, C
700	1		_aSieberts, S
700	1		_aNayee, J
700	1		_aMeehan, A G
700	1		_aShapiro, D
700	1		_aHeymsfield, S B
700	1		_aKaufman, K D
700	1		_aAmatruda, J M
773	0		_tInternational journal of obesity (2005) _gvol. 34 _gno. 5 _gp. 919-35
856	4	0	_uhttps://doi.org/10.1038/ijo.2010.21 _zAvailable from publisher's website
999			_c19527494 _d19527494